Core Viewpoint - Aiwai Technology (688067.SH) announced a joint investment of 30 million yuan in Luying Technology, indicating a strategic move to expand its portfolio in the medical imaging sector [1] Group 1: Investment Details - The company will contribute 10 million yuan to the investment, resulting in a 9.0744% equity stake in Luying Technology after the capital increase [1] - The investment is made in collaboration with Guangzhou Guangjin Life Health Industry Investment Fund and Hunan Xiangjiang New Area Guidance No. 1 Venture Capital Partnership [1] Group 2: Company and Product Status - Luying Technology is a relatively new company that currently has no sales revenue and has not yet achieved profitability [1] - The core product, high-end medical imaging SPECT/CT, is still under development, with uncertainties regarding successful research and the completion of medical device certification [1]

Core Viewpoint - Aivi Technology (688067) plans to invest 30 million yuan in Hunan Luying Technology Co., Ltd. by subscribing to its newly registered capital of 7.4813 million yuan, acquiring a 9.07% stake post-investment [1] Group 1 - Aivi Technology will contribute 10 million yuan to the investment [1] - The investment is made in collaboration with state-owned investment institutions, Guangzhou Guangjin Life Health Industry Investment Fund and Hunan Xiangjiang New Area Guidance No. 1 Venture Capital Partnership [1] - The total investment amount for the project is 30 million yuan [1]

爱威科技(688067.SH)公告，公司以自有资金出资1000万元对麓影科技进行增资。增资完成后，公司将 持有麓影科技9.0744%的股权。据公告信息所示，麓影科技主营业务为国产化高分辨率单光子发射计算 机断层扫描仪(SPECT)及其核心元器件的开发，为医院提供精准、安全、经济、便捷的分子影像诊断技 术方案。核心产品是国产化SPECT和SPECT/CT及其核心元器件，属于高端核医学影像诊疗设备。 ...

Core Viewpoint - The company Awei Technology (688067.SH) has announced an investment of 10 million yuan in Luying Technology, acquiring a 9.0744% stake in the latter [1] Company Summary - Awei Technology is investing its own funds to enhance its stake in Luying Technology, indicating a strategic move to strengthen its position in the high-end medical imaging sector [1] - Luying Technology specializes in the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components, providing advanced molecular imaging diagnostic solutions for hospitals [1] Industry Summary - The core products of Luying Technology include domestically produced SPECT and SPECT/CT systems, which are categorized as high-end nuclear medicine imaging and diagnostic equipment [1]

Core Insights - Awei Technology's stock decreased by 1.51% on October 9, with a trading volume of 37.03 million yuan [1] - The company reported a financing buy-in of 4.30 million yuan and a net financing buy of 0.96 million yuan on the same day [1][2] - As of October 9, the total financing and securities lending balance for Awei Technology was 47.96 million yuan, accounting for 2.76% of its market capitalization [1] Financing Overview - On October 9, Awei Technology had a financing buy-in of 4.30 million yuan, with a financing balance of 47.96 million yuan, which is above the 80th percentile of the past year [1] - The company had no securities lending activity on October 9, with a securities lending balance of 0.00 yuan, indicating a high level of inactivity in this area [1] Business Performance - As of June 30, Awei Technology had 4,086 shareholders, an increase of 13.34% from the previous period, while the average circulating shares per person decreased by 11.77% [2] - For the first half of 2025, Awei Technology achieved a revenue of 110 million yuan, representing a year-on-year growth of 12.70%, and a net profit of 14.06 million yuan, up 21.16% year-on-year [2] Dividend Information - Since its A-share listing, Awei Technology has distributed a total of 40.73 million yuan in dividends, with 20.33 million yuan distributed over the past three years [3] - As of June 30, 2025, the ninth largest circulating shareholder is Nuoan Multi-Strategy Mixed A, holding 477,400 shares as a new shareholder, while Anxin Medical Health Stock A has exited the top ten circulating shareholders [3]

Core Points - The company has obtained a total of 4 domestic patent certificates, including 2 invention patents and 2 design patents, as well as 2 foreign patents, 3 computer software copyright registration certificates, and 1 Class I medical device filing certificate from July 1, 2025, to September 30, 2025 [1][2][3] Group 1: Patent Certificates - The acquisition of the patents reflects the company's core technology and will enhance its intellectual property protection system, promoting technological innovation and improving core competitiveness [1][2] - The recent patent acquisitions are not expected to have a significant impact on the company's short-term operations [1][2] Group 2: Computer Software Copyright - The obtained computer software copyright registration certificates will help enhance the company's core competitiveness and support the establishment of a continuous innovation mechanism [2] Group 3: Medical Device Filing - The Class I medical device filing certificate will diversify the company's product offerings and meet market demand, thereby strengthening its core competitiveness [3] - The sales performance of the products post-launch will depend on future market promotion efforts, and the company cannot currently predict the specific impact on future revenue [3]

关于取得专利证书、软件著作权登记证书 及医疗器械备案凭证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司（以下简称"公司"）及其子公司自 2025 年 7 月 1 日起至 2025 年 9 月 30 日共取得境内专利证书 4 项，其中发明专利 2 项、外观 设计专利 2 项；取得境外专利 2 项；取得计算机软件著作权登记证书 3 项；取 得第一类医疗器械备案凭证 1 项。具体情况如下： 一、专利证书 | 序 | 专利名称 | 专利号 | 专利权人 | 申请日期 | 专利 | 取得 | 授权日期 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | | 类别 | 方式 | | | 1 | 一种医疗检验用 废液收集处理装 | ZL202510065768.5 | 爱威科技 | 2025/01/16 | 发明 | 自主 研发 | 2025/04/29 | | | 置 | | | | | | | | 2 | 一种拭子采样 ...

证券日报网讯9月24日晚间，爱威科技发布公告称，近日，公司已完成工商变更登记和章程备案手续， 并取得了湖南湘江新区管理委员会行政审批服务局换发的《营业执照》。 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-040 爱威科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱威科技股份有限公司（以下简称"公司"）分别于 2025 年 8 月 28 日召开 第五届董事会第五次会议、2025 年 9 月 17 日召开 2025 年第一次临时股东大会， 审议通过了《关于变更经营范围、取消监事会及修订<公司章程>并办理相应工商 变更登记的议案》,具体内容详见公司于 2025 年 8 月 29 日在上海证券交易所网 站（www.sse.com.cn）披露的《关于变更经营范围、取消监事会、修订<公司章 程>、制定及修订部分治理制度并办理相应工商变更登记的公告》。 近日，公司已完成工商变更登记和章程备案手续，并取得了湖南湘江新区管 理委员会行政审批服务局换发的《营业执照》，变更后的具体登记信息如下： 统一社会信用代码：914301001838986849 注册资本：陆仟捌佰万元整 类型：股份有限公司（上市、自然人投资或控股） ...

Group 1 - The core point of the news is that Aiwei Technology's stock has experienced a decline of 5.25% on September 23, with a total market value of 1.645 billion yuan and a cumulative drop of 3.44% over three consecutive days [1] - Aiwei Technology, established on March 16, 2000, and listed on June 16, 2021, specializes in the research, production, sales, and service of medical clinical testing analysis instruments and related in vitro diagnostic reagents and medical consumables [1] - The revenue composition of Aiwei Technology includes reagents at 45.63%, instruments at 34.53%, consumables at 17.56%, and others at 2.28% [1] Group 2 - According to data, the top circulating shareholder of Aiwei Technology is the Nuoan Multi-Strategy Mixed A Fund (320016), which entered the top ten shareholders in the second quarter with 477,400 shares, accounting for 0.7% of circulating shares [2] - The estimated floating loss for the Nuoan Multi-Strategy Mixed A Fund today is approximately 639,700 yuan, with a floating loss of 434,400 yuan during the three-day decline [2] - The Nuoan Multi-Strategy Mixed A Fund has a total scale of 1.399 billion yuan and has achieved a return of 57.56% this year, ranking 694 out of 8,172 in its category [2] Group 3 - The fund managers of Nuoan Multi-Strategy Mixed A are Kong Xianzheng and Wang Haichang, with Kong having a tenure of 4 years and 302 days and a best fund return of 72.6% during his tenure [3] - Wang Haichang has a tenure of 3 years and 64 days, with a best fund return of 60.45% during his tenure [3]